These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1089 related articles for article (PubMed ID: 2971797)
1. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. Sonsalla PK; Manzino L; Heikkila RE J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797 [TBL] [Abstract][Full Text] [Related]
2. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
3. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems. Wachtel SR; Hu XT; Galloway MP; White FJ Synapse; 1989; 4(4):327-46. PubMed ID: 2532422 [TBL] [Abstract][Full Text] [Related]
4. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus. Carlson JH; Bergstrom DA; Demo SD; Walters JR Synapse; 1990; 5(2):83-93. PubMed ID: 2309160 [TBL] [Abstract][Full Text] [Related]
5. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
6. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons. Kelland MD; Freeman AS; Chiodo LA Synapse; 1988; 2(4):416-23. PubMed ID: 2973142 [TBL] [Abstract][Full Text] [Related]
7. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Weick BG; Walters JR Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219 [TBL] [Abstract][Full Text] [Related]
8. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. DeBoer P; Abercrombie ED J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558 [TBL] [Abstract][Full Text] [Related]
9. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Hu XT; White FJ Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772 [TBL] [Abstract][Full Text] [Related]
10. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures. Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L Synapse; 1990; 5(2):113-9. PubMed ID: 2137942 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output. Huang KX; Walters JR J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456 [TBL] [Abstract][Full Text] [Related]
12. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. Hossain MA; Weiner N J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772 [TBL] [Abstract][Full Text] [Related]
13. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine. Sprah L; Zivin M; Sket D J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846 [TBL] [Abstract][Full Text] [Related]
15. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats. Hossain MA; Weiner N J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556 [TBL] [Abstract][Full Text] [Related]
16. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. Hu XT; Wachtel SR; Galloway MP; White FJ J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947 [TBL] [Abstract][Full Text] [Related]
17. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists. McPherson RJ; Marshall JF Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899 [TBL] [Abstract][Full Text] [Related]
19. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. Boldry RC; Chase TN; Engber TM J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors. Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]